Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CCR1 | P32246 | 2/20 | 0.50 |
| ▸ | CCR5 | P51681 | 2/20 | 0.50 |
| ▸ | CCR8 | P51685 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28444772 | 0.86 | NR1H2 (0.47) | CYP1A2GRM5CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL21091019 | 0.85 | GRM5 (0.45) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL14678660 | 0.85 | KDM4E (0.46) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL24888335 | 0.83 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL21666537 | 0.83 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL12558190 | 0.83 | KDM4E (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL4725082 | 0.82 | CYP1A2 (0.49) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL2529950 | 0.81 | GRM5 (0.60) | CYP1A2GRM5BRD4CYP2D6CYP19A1 | |
| SCHEMBL12164836 | 0.80 | NPC1 (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL23346997 | 0.80 | KDM4E (0.42) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225184-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230200211-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4016656-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | Samsung Electronics Co., Ltd. (KR) | 2022-06-22 | — | — | EP | disclosed |
| CN-112759580-B | Preparation method of chroman-4-one and derivatives thereof | 河南大学 | 2022-05-17 | — | — | CN | disclosed |
| EP-3330262-B1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DIODE CONTAINING SAME | LG CHEMICAL LTD (KR) | 2021-07-28 | — | — | EP | disclosed |
| WO-2021006532-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME | 주식회사 엘지화학 | 2021-01-14 | — | — | WO | disclosed |
| US-10487099-B2 | Synthesis of hypervalent iodine reagents with dioxygen | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2019-11-26 | — | — | US | disclosed |
| US-20190002487-A1 | SYNTHESIS OF HYPERVALENT IODINE REAGENTS WITH DIOXYGEN | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2019-01-03 | — | — | US | disclosed |
| CN-104816104-B | Ag balls, Ag cores ball, scaling powder coating Ag balls, scaling powder coating Ag cores ball, solder joints, forming solder, soldering paste | 千住金属工业株式会社 | 2018-07-03 | — | — | CN | disclosed |
| US-9966538-B2 | Compound, light-emitting element and electronic device comprising same | LMS CO., LTD. (KR) | 2018-05-08 | — | — | US | disclosed |
| EP-2313472-B1 | AZAPYRENES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2012-08-15 | — | — | EP | disclosed |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| CN-101835745-A | Method for producing disulfonic acid compound, asymmetric mannich catalyst, method for producing beta-aminocarbonyl derivative, and novel disulfonate | UNIV NAGOYA NAT UNIV CORP | 2010-09-15 | — | — | CN | disclosed |
| EP-1773877-B1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008024953-A2 | TRANSITION METAL-CATALYZED ALKYLATION OF C-H BONDS WITH ORGANOBORON REAGENTS | BRANDEIS UNIVERSITY (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024953-A2 | TRANSITION METAL-CATALYZED ALKYLATION OF C-H BONDS WITH ORGANOBORON REAGENTS | BRANDEIS UNIVERSITY (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007140284-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| US-6686345-B2 | INCLUDES AN AZA-ENEDIYNE, AZA-ENYNE ALLENE, OR AN AZA-DIALLENE; ARE PREFERABLY NON-HYDROLYZABLE, CATIONIC COMPOUNDS THAT BIND TO NUCLEIC ACIDS. | RESEARCH DEVELOPMENT FOUNDATION | 2004-02-03 | — | — | US | disclosed |
| US-20020132797-A1 | DNA-cleaving antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | KDM4E 2337/4885LMNA 3777/4885CCR1 3289/4885 |
| US-20230225184-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ESRRG, TECR, OXSR1 | KDM4E 2670/4885LMNA 2291/4885CCR1 1026/4885 |
| US-20230200211-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OPRM1, OCIAD1 | KDM4E 2956/4885LMNA 701/4885CCR1 934/4885 |
| US-20190002487-A1 | SYNTHESIS OF HYPERVALENT IODINE REAGENTS WITH DIOXYGEN | TPO, HAO2, OGFOD1 | KDM4E 2775/4885LMNA 4840/4885CCR1 4594/4885 |
| US-20020132797-A1 | DNA-cleaving antitumor agents | DNASE1, DNASE1L3, DCLRE1B | KDM4E 1073/4885LMNA 339/4885CCR1 3727/4885 |
| US-10487099-B2 | Synthesis of hypervalent iodine reagents with dioxygen | TPO, HAO2, OGFOD1 | KDM4E 2775/4885LMNA 4840/4885CCR1 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.